643 related articles for article (PubMed ID: 12032333)
21. Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells.
Carter BZ; Mak PY; Mak DH; Ruvolo VR; Schober W; McQueen T; Cortes J; Kantarjian HM; Champlin RE; Konopleva M; Andreeff M
Oncotarget; 2015 Oct; 6(31):30487-99. PubMed ID: 26431162
[TBL] [Abstract][Full Text] [Related]
22. No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
La Rosée P; Shen L; Stoffregen EP; Deininger M; Druker BJ
Hematol J; 2003; 4(6):413-9. PubMed ID: 14671613
[TBL] [Abstract][Full Text] [Related]
23. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
[TBL] [Abstract][Full Text] [Related]
24. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
25. Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines.
van der Kuip H; Moehring A; Wohlbold L; Miething C; Duyster J; Aulitzky WE
Leuk Res; 2004 Apr; 28(4):405-8. PubMed ID: 15109541
[TBL] [Abstract][Full Text] [Related]
26. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis.
Nakajima A; Tauchi T; Ohyashiki K
Leukemia; 2001 Jun; 15(6):989-90. PubMed ID: 11417489
[No Abstract] [Full Text] [Related]
27. Role of anti-apoptotic pathways activated by BCR/ABL in the resistance of chronic myeloid leukemia cells to tyrosine kinase inhibitors.
Danisz K; Blasiak J
Acta Biochim Pol; 2013; 60(4):503-14. PubMed ID: 24273759
[TBL] [Abstract][Full Text] [Related]
28. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.
Donato NJ; Wu JY; Stapley J; Gallick G; Lin H; Arlinghaus R; Talpaz M
Blood; 2003 Jan; 101(2):690-8. PubMed ID: 12509383
[TBL] [Abstract][Full Text] [Related]
29. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis.
Sacha T; Hochhaus A; Hanfstein B; Müller MC; Rudzki Z; Czopek J; Wolska-Smoleń T; Czekalska S; Salamanchuk Z; Jakóbczyk M; Skotnicki AB
Leuk Res; 2003 Dec; 27(12):1163-6. PubMed ID: 12921956
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
[TBL] [Abstract][Full Text] [Related]
31. Regulation of myeloid leukaemia by the cell-fate determinant Musashi.
Ito T; Kwon HY; Zimdahl B; Congdon KL; Blum J; Lento WE; Zhao C; Lagoo A; Gerrard G; Foroni L; Goldman J; Goh H; Kim SH; Kim DW; Chuah C; Oehler VG; Radich JP; Jordan CT; Reya T
Nature; 2010 Aug; 466(7307):765-8. PubMed ID: 20639863
[TBL] [Abstract][Full Text] [Related]
32. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
33. Pathobiology of lymphoid and myeloid blast crisis and management issues.
Ilaria RL
Hematology Am Soc Hematol Educ Program; 2005; ():188-94. PubMed ID: 16304379
[TBL] [Abstract][Full Text] [Related]
34. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Thiesing JT; Ohno-Jones S; Kolibaba KS; Druker BJ
Blood; 2000 Nov; 96(9):3195-9. PubMed ID: 11050003
[TBL] [Abstract][Full Text] [Related]
36. [Gene of DNA-dependent protein kinase catalylic subunit in chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Apr; 15(2):248-52. PubMed ID: 17493325
[TBL] [Abstract][Full Text] [Related]
37. Clonal evolution with inv(11)(p15q22) and NUP98/DDX10 fusion gene in imatinib-resistant chronic myelogenous leukemia.
Yamamoto M; Kakihana K; Kurosu T; Murakami N; Miura O
Cancer Genet Cytogenet; 2005 Mar; 157(2):104-8. PubMed ID: 15721630
[TBL] [Abstract][Full Text] [Related]
38. NUP98-HOXA9 bearing therapy-related myeloid neoplasm involves myeloid-committed cell and induces HOXA5, EVI1, FLT3, and MEIS1 expression.
Burillo-Sanz S; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; García-Lozano JR; Falantes JF; Prats-Martín C; Bernal R; Pérez-Simón JA
Int J Lab Hematol; 2016 Feb; 38(1):64-71. PubMed ID: 26418229
[TBL] [Abstract][Full Text] [Related]
39. BCR/ABL-mediated increased expression of multiple known and novel genes that may contribute to the pathogenesis of chronic myelogenous leukemia.
Salesse S; Verfaillie CM
Mol Cancer Ther; 2003 Feb; 2(2):173-82. PubMed ID: 12589034
[TBL] [Abstract][Full Text] [Related]
40. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
